Cytisinicline + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vaping Cessation
Conditions
Vaping Cessation
Trial Timeline
May 15, 2026 → Sep 30, 2027
NCT ID
NCT07392125About Cytisinicline + Placebo
Cytisinicline + Placebo is a phase 3 stage product being developed by Achieve Life Sciences for Vaping Cessation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07392125. Target conditions include Vaping Cessation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07392125 | Phase 3 | Recruiting |
| NCT05431387 | Phase 2 | Completed |
| NCT05206370 | Phase 3 | Completed |
| NCT04576949 | Phase 3 | Completed |
Competing Products
1 competing product in Vaping Cessation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cytisinicline + Placebo | Achieve Life Sciences | Phase 2 | 44 |